Logo

Lilly Signs a License Agreement with Lycia to Develop Novel LYTAC Degraders

Share this

Lilly Signs a License Agreement with Lycia to Develop Novel LYTAC Degraders

Shots:

  • Lycia to receive $35M up front and is also eligible to receive an additional ~$1.6B upon the achievement of milestones along with royalties on sales of the product emerges from the collaboration
  • Lilly will be responsible for the pre/clinical development of the product and also gets an exclusive global license to commercialize the product
  • The collaboration will utilize Lycia's LYTAC platform to develop novel degraders for up to five targets to address unmet medical needs in immunology and pain

Click here  | Ref: Eli Lilly | Image: Fox Business

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions